Souvenaid

Souvenaid is a medical food rather than a drug, meaning it is a specially formulated product intended for the dietary management of a specific condition, in this case Alzheimer's disease ^[1]. It is taken as a small once-daily drink and is marketed by the nutrition company Nutricia, part of Danone. The concept behind it grew out of research suggesting that the loss of synapses, the connections between brain cells, is an early feature of Alzheimer's disease, and that certain nutrients are needed to build new synaptic membranes ^[2].

The active component is a patented nutrient blend called Fortasyn Connect. It brings together the omega-3 fatty acids docosahexaenoic acid and eicosapentaenoic acid, together with uridine monophosphate, choline, and phospholipids, which serve as building blocks for cell membranes, plus supporting cofactors including B vitamins, folic acid, vitamins C and E, and selenium ^[1][2]. These ingredients were chosen to supply substances that are often found at low levels in people with Alzheimer's disease ^[2].

Souvenaid has been tested in several randomized controlled trials, including studies known as Souvenir I and II, S-Connect, and the longer LipiDiDiet trial ^[2]. Results have been mixed. In people with mild-to-moderate Alzheimer's dementia, adding the drink did not slow cognitive decline compared with a control product ^[3]. In earlier, prodromal disease the LipiDiDiet trial missed its main cognitive target but suggested benefits on some secondary measures, including specific cognitive domains and shrinkage of the hippocampus ^[2]. A 2020 Cochrane systematic review concluded that, over two years, Souvenaid probably does not reduce the risk of progressing to dementia and produces little or no clear benefit on cognition or everyday function, while noting that side effects were uncommon ^[1].

As a medical food, Souvenaid is regulated differently from a pharmaceutical and is intended for use under medical supervision rather than as an approved treatment that alters the disease. It has been marketed in a number of European countries and in Australia. Its marketing claims have faced scrutiny; some regulators have declined to endorse cognitive benefit claims, reflecting the limited and inconsistent trial evidence.

Generally well tolerated as a food, with occasional GI complaints. It contains common nutrients at nutritional doses, so serious side effects are uncommon; people with allergies to milk or fish-derived components should check ingredients. It is meant to complement, not replace, medical care for cognitive disorders.